NCT01123083View on ClinicalTrials.gov

Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2

PHASE3CompletedINTERVENTIONAL
Enrollment

179

Participants

Timeline

Start Date

May 17, 2010

Primary Completion Date

March 9, 2012

Study Completion Date

March 9, 2012

Conditions
Diabetes Mellitus, Type 1
Interventions
BIOLOGICAL

Otelixizumab

infusion

BIOLOGICAL

Placebo

Infusion

Trial Locations (1)

00155

GSK Investigational Site, Roma

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

Juvenile Diabetes Research Foundation

OTHER

lead

GlaxoSmithKline

INDUSTRY